Lantheus

Lantheus develops, manufactures, and commercializes radiopharmaceuticals, diagnostic imaging agents, and precision medicine technologies for oncology, cardiology, and other disease areas. The company provides positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging agents, targeted radiopharmaceuticals,ultrasound contrast agents, and nuclear medicine products that support disease detection, diagnosis, treatment planning, and therapeutic monitoring. Its portfolio also includes radiopharmaceutical manufacturing, isotope production, artificial intelligence–enabled imaging solutions, biomarker development, contract manufacturing, and strategic partnerships that support precision medicine and drug development. Lantheus conducts research, clinical development, regulatory activities, and commercial manufacturing to advance diagnostic and therapeutic radiopharmaceuticals, including targeted oncology products and companion diagnostics. The company's technologies are designed to help healthcare providers, imaging centers, hospitals, and pharmaceutical partners improve disease detection, treatment selection, and patient management through molecular imaging and targeted radiopharmaceutical therapies.